Fresenius SE & Co. KGaA Stock Timeline

2026 (May–Aug)

Strong operational momentum and upgraded guidance following Q1 and Q2 results marked a shift in market perception toward sustainable earnings growth and balance-sheet repair. S&P revised its outlook to positive, and the company issued bonds.

Q1 2026 showed group revenue of €5,744m with 5% organic growth. Core earnings per share grew 13% in constant currency terms. Q2 2026 delivered group revenue of €5,864m with 6% organic growth, group EBIT of €719m, and an EBIT margin of 12.3%. Core EPS reached €0.83 in constant currency, up 14% for the half-year. S&P affirmed the BBB rating and changed its outlook from Stable to Positive. On July 8, 2026, Fresenius issued €1,000m in bonds.

Investors interpreted these results as evidence that Fresenius was converting restructuring gains into durable earnings expansion and financial stability—a transition from turnaround to growth with improved credit standing.

2025 (full year; results announced Feb 25, 2026)

FY/2025 results marked the launch of the "Rejuvenate" phase of #FutureFresenius. Management upgraded guidance during the year and continued portfolio simplification, including a decision to reduce the stake in Fresenius Medical Care.

Group revenue reached €22,554m with 7% organic growth. EBIT rose 13% and core EPS grew 12%, both in constant currency and excluding Fresenius Medical Care. Net debt fell by around €3bn over the prior two years through end-2025. The company proposed a dividend increase for the 2026 AGM.

The market read 2025 as the pivot from restructuring to value creation. After the RESET and Revitalize phases, Rejuvenate represented the earnings-growth phase. Consistent organic expansion, margin improvement, and deleveraging shifted sentiment from cyclical recovery toward sustainable operational improvement.

2024 (calendar year and FY/2024 disclosures)

Continued execution of the #FutureFresenius strategy saw portfolio moves and improving profitability across core businesses, laying groundwork for the Rejuvenate phase in 2025.

FY/2024 reported revenue around €21.8bn with headline EPS improvements versus 2023. The RESET phase began in 2022, followed by Revitalize actions through 2023–2024.

Markets increasingly viewed Fresenius as de-risked. Operational focus on higher-return growth vectors—notably Fresenius Kabi growth initiatives and Helios hospital performance—combined with disciplined portfolio management to improve investor confidence, though legacy exposure to Fresenius Medical Care and leverage remained watchpoints.

2023 (operational focus, portfolio optimization)

Ongoing Revitalize actions built "growth vectors," particularly in Fresenius Kabi, while the Fresenius Helios hospital network showed operational improvement.

Investors began to reward clearer strategy and early signs of margin recovery. Sentiment shifted from caution about execution risk toward guarded optimism as core businesses delivered steady results and management emphasized returns and cash-generation priorities.

2022 (Oct 1, 2022 — Management change and Reset strategy launch)

Michael Sen was appointed CEO effective October 1, 2022. The company announced and began implementing "RESET," focusing on returns, productivity, and balance-sheet repair.

The management change signaled a strategic reset that markets read as a decisive step to address structural issues around leverage and margins. Initial investor perception centered on a high-risk, high-reward turnaround: success would mean restored profitability and de-risking; failure would leave legacy problems unresolved.

2021 (context: pandemic aftermath and business pressures)

Post-COVID normalization in healthcare demand continued alongside pressure on some business lines through costs, supply-chain disruption, and outpatient service shifts, setting conditions for the 2022–2025 strategic program.

Investors treated Fresenius as still recovering from pandemic-related revenue shifts and structural challenges. The company's multi-year strategy to rebuild margins and reduce leverage lacked evidence-based backing, so sentiment remained cautious and valuation reflected execution risk.